An Open-Label, Single-Dose, Crossover Study of the Pharmacokinetics and Metabolism of Two Oral Formulations of 1-Octanol in Patients with Essential Tremor

Neurotherapeutics

Volumn 8, Issue 4, 2011, Pages 753-762

  Nahab, Fatta B ^a   Wittevrongel, Loretta ^b   Ippolito, Dominic ^b   Toro, Camilo ^b   Grimes, George J ^c   Starling, Judith ^c   Potti, Gopal ^c   Haubenberger, Dietrich ^b,d   Bowen, Daniel ^e   Buchwald, Peter ^a   Dong, Chuanhui ^a   Kalowitz, Daniel ^f   Hallett, Mark ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e WAKE FOREST UNIVERSITY   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

1 Octanol; Alcohol; Essential tremor; Octanoic acid; Spirography; Therapeutics

Indexed keywords

CARBOXYLIC ACID; OCTANOIC ACID; OCTANOL;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DYSGEUSIA; ELECTROCARDIOGRAM; ESSENTIAL TREMOR; FEMALE; GAIT; HEALTH SURVEY; HUMAN; INTOXICATION; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SPEECH DISORDER; SPIROGRAPHY; TREATMENT DURATION; TREMOR; VITAL SIGN;

1-OCTANOL; ADMINISTRATION, ORAL; AGED; CAPRYLATES; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ESSENTIAL TREMOR; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; SOLVENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 80955157841     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-011-0045-1     Document Type: Article

References (22)

1. Deuschl G, Raethjen J, Lindemann M, Krack P. The pathophysiology of tremor. Muscle Nerve 2001; 24: 716-735.
2. Koller WC, Busenbark K, Miner K. The relationship of essential tremor to other movement disorders: report on 678 patients. Essential Tremor Study Group. Ann Neurol 1994; 35: 717-723.
3. Sinton CM, Krosser BI, Walton KD, Llinas RR. The effectiveness of different isomers of octanol as blockers of harmaline-induced tremor. Pflugers Arch 1989; 414: 31-36.
4. Koller WC, Biary N. Effect of alcohol on tremors: comparison with propranolol. Neurology 1984; 34: 221-222.
5. Bushara K, Goldstein S, Grimes G, Burstein A, Hallett M. Pilot trial of 1-octanol in essential tremor. Neurology 2004; 62: 122-124.
6. Shill HA, Bushara KO, Mari Z, Reich M, Hallett M. Open-label dose-escalation study of oral 1-octanol in patients with essential tremor. Neurology 2004; 62: 2320-2322.
7. Hinson JA, Neal RA. An examination of octanol and octanal metabolism to octanoic acid by horse liver alcohol dehydrogenase. Biochimica et Biophysica Acta 1975; 384: 1-11.
8. Fahn S, Tolosa E, Marin C. Clinical rating scale for tremor. In: Jankovic J. Tolosa E, eds. Parkinson's disease and movement disorders, 2nd ed. Baltimore: Williams and Wilkins, 1993: 271-280.
9. Bain P, Brin M, Deuschl G, et al. Criteria for the diagnosis of essential tremor. Neurology 2000; 54(11 suppl 4): S7.
10. Haubenberger D, Kalowitz D, Nahab FB, et al. Validation of computerized essential tremor spiral analysis as outcome parameter for clinical trials in essential tremor. Mov Disord (under review).
11. Haubenberger D, Kalowitz D, Nahab FB, et al. Validity and reliability of computerized tremor spirography as outcome measure for clinical trials in essential tremor. Neurology 2010(2): A349, P04. 126.
12. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, version 3. 0; 2003. Available from: http://ctep. cancer. gov.
13. Gabrielsson J, Weiner D. Pharmacokinetic/pharmacodynamic data analysis: concepts and applications, 3rd ed. Apotekarsocieteten, ed. Stockholm: Swedish Pharmaceutical Press; 2000.
14. Louis E. Clinical practice. Essential tremor. NEJM 2001; 345: 887-891.
15. Food and Drug Administration, 2000. Doc. No. #1145. In: Food Safety Additive Profile and § 184. 1025.
16. Rappaport MS, Gentry RT, Schneider DR, Dole VP. Ethanol effects on harmaline-induced tremor and increase of cerebellar cyclic GMP. Life Sci 1984; 34: 49-56.
17. McCreery MJ, Hunt WA. Physico-chemical correlates of alcohol intoxication. Neuropharmacology 1978; 17: 451-461.
18. Lyon RC, McComb JA, Schreurs J, Goldstein DB. A relationship between alcohol intoxication and the disordering of brain membranes by a series of short-chain alcohols. J Pharmacol Exp Ther 1981; 218: 669-675.
19. Wakabayashi T, Adachi K, Popinigis J. Effects of alkyl alcohols and related chemicals on rat liver structure and function. I. Induction of two distinct types of megamitochondria. Acta Pathol Jpn 1991; 41: 405-413.
20. Jelski W, Chrostek L, Szmitkowski M, Laszewicz W. Activity of class I, II, III, and IV alcohol dehydrogenase isoenzymes in human gastric mucosa. Dig Dis Sci 2002; 47: 1554-1557.
21. Schwabe AD, Bennett LR, Bowman LP. Octanoic acid absorption and oxidation in humans. J Appl Physiol 1964; 19: 335-337.
22. Traul KA, Driedger A, Ingle DL, Nakhasi D. Review of the toxicologic properties of medium-chain triglycerides. Food Chem Toxicol 2000; 38: 79-98.